APM (APM, Financial) experienced a significant stock price drop of 5.41%. The stock is currently trading at $0.700 per share with a trading volume of 13,747 shares and a turnover rate of 0.25%, showing a price fluctuation of 4.05%.
Recent financial reports reveal that APM posted a revenue of $431,378 and a net loss of $2.82 million, resulting in an earnings per share (EPS) of -$0.62. The gross profit was reported at -$1.11 million, and the price-to-earnings (P/E) ratio stands at -1.16. No institutional ratings are currently available for APM regarding buy, hold, or sell recommendations.
Within the biotechnology sector, where APM operates, the overall growth was 1.67%. Notable performers in the sector included Exicure, Inc., Apollomics Inc C/Wts 01/04/2028 (To Pur Ord), and Conduit Pharmaceuticals Inc C/Wts 22/09/2028 (To Pur Com), which saw significant gains. Active stocks with high turnover rates included Cassava Sciences, Inc., Cognition Therapeutics, Inc., and Exicure, Inc., with turnover rates of 153.42%, 106.71%, and 87.03%, respectively. Stocks with notable price fluctuations included Apollomics Inc C/Wts 01/04/2028 (To Pur Ord), Rocket Pharmaceuticals Inc C/Wts 02/09/2026 (To Pur Com), and Exicure, Inc., with fluctuations of 95.05%, 85.86%, and 75.84%, respectively.
APM is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for unmet medical needs, particularly in oncology, including orphan oncology indications, and infectious diseases. The company operates through two segments: therapeutic and non-therapeutic projects, including ALS-4, SACT-1, and RPIDD. APM also provides healthcare services.
